ImmunityBio Simulations give clue to why South African strain of SARS-CoV-2 is rapidly spreading
Using Molecular Dynamic (MD) simulation, ImmunityBio scientists assessed the affinity of mutated spike receptor-binding domain…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ImmunityBio
ImmunityBio and NantKwest announce merger
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined…
ImmunityBio COVID-19 vaccine candidate shows protection of airways in non-human primates
The hAd5-COVID-19 candidate is designed to address a potential problem that may emerge when first-generation adenoviral platforms…
ImmunityBio, NantKwest begin patient dosing in Phase 1 clinical trial of COVID-19 vaccine candidate
The Phase 1 trial, being conducted at the Hoag Hospital in Newport Beach, California, is enrolling healthy adult subjects up to…
US FDA authorises phase 1 trial of ImmunityBio’s COVID-19 vaccine candidate hAd5
Ongoing development proceeding for oral, inhalational and intranasal administration of hAd5